Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
NCT ID: NCT07000253
Last Updated: 2025-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2/PHASE3
290 participants
INTERVENTIONAL
2026-01-31
2034-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases.
Background:
In about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemic therapy should last before initiating local treatment. The OMEC-5 study aims to clarify this and identify potential biomarkers for treatment response.
Study Design:
Initiated by Amsterdam UMC and UMCU and conducted in multiple hospitals across Europe.
Total of 414 patients to be enrolled.
Duration: \~53 months (35 months enrollment + 18 months follow-up).
Approved by the medical ethics committee at Amsterdam UMC.
Procedure:
Eligibility screening: Includes physical exam, blood tests (incl. circulating tumor cells), medical history review, and confirmation of oligometastases by an expert panel.
Initial treatment: All participants receive 4 months of standard systemic therapy (chemotherapy + immunotherapy and/or targeted therapy depending on tumor markers like HER2 or Claudin 18.2).
Response assessment (Review 1): Imaging and/or laparoscopic examination.
If oligometastases persist and tumors have not progressed, participants are randomized into two groups:
Group A (longer systemic therapy): 4 more months of systemic therapy, then local treatment if disease is stable, followed by 4 months of immunotherapy ± targeted therapy.
Group B (shorter systemic therapy): Immediate local treatment followed by 4 months of systemic therapy, then reassessment and potentially 4 months of immunotherapy ± targeted therapy.
Follow-up: Regular scans and quality-of-life questionnaires (5 times), and periodic blood sampling (4 times).
Treatments Involved:
Chemotherapy: CapOx or FOLFOX
Immunotherapy: nivolumab or pembrolizumab
Targeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive)
Potential Benefits and Risks:
Patients may benefit from better disease control and a personalized treatment strategy.
Known side effects relate to the standard treatments used (chemo, immuno, targeted therapies), and no extra medical risk is expected beyond routine care.
Possible inconveniences include blood draws, scans, minor surgery (laparoscopy), and time investment.
Data and Sample Handling:
Personal data and tumor/blood samples are coded and securely stored.
Data may be used for future cancer research if the patient consents.
Participants can withdraw at any time.
Confidentiality and Privacy:
Patient data are kept confidential, and participants have rights to access or delete their data. Privacy measures comply with GDPR and Dutch law.
Compensation and Insurance:
Participation is voluntary, with no financial compensation. Standard treatment costs are covered by healthcare insurance. No extra insurance is required, as the treatment aligns with standard care practices.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
NCT03161522
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00069953
Chemoradiation and Panitumumab for Esophageal Cancer
NCT01077999
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
NCT00002631
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
NCT00008047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
long duration of systemic therapy
Patients with no disease progression at 4 months (18 weeks) after systemic therapy with oxaliplatin, fluorpyrimidine, checkpoint inhibitor and/or taregted therapy and fit for local treatment will receive 4 additional months of systemic therapy and subsequent evaluation for local treatment to all disease sites.
Chemotherapy
Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
Targeted Systemic Therapy
Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
Immunotherapy
Biomarker selected patients will recieve checkpoint inhibitors according to standard care
Surgery
If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
Radiotherapy
Metastases may be irradiated
Short duration of systemic therapy
Patients with no disease progression at 4 months (18 weeks) after systemic therapy oxaliplatin, fluorpyrimidine, checkpoint inhibitor and/or targeted therapy and fit for local treatment will recieve direct local treatment to all disease sites.
Chemotherapy
Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
Targeted Systemic Therapy
Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
Immunotherapy
Biomarker selected patients will recieve checkpoint inhibitors according to standard care
Surgery
If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
Radiotherapy
Metastases may be irradiated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
Targeted Systemic Therapy
Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
Immunotherapy
Biomarker selected patients will recieve checkpoint inhibitors according to standard care
Surgery
If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
Radiotherapy
Metastases may be irradiated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide written informed consent
* Histologically confirmed esophageal, gastric or gastroesophageal junction tumor with oligometastatic (M1) disease defined according to the OMEC consensus statement:
* One organ with ≤3 metastases or 1 involved extra-regional lymph node station (based on the TNM 8 classification)
* ≤3 unilobar liver metastases or ≤2 bilobar liver metastases
* ≤ 3 unilateral lung metastases
* Unilateral adrenal gland involvement
* Metastasis confined to 1 bone structure or 1 soft tissue compartment
* Synchronous oligometastatic disease with a resectable primary tumor or metachronous oligometastatic disease (in the event of a locoregional recurrence this should be resectable)
* Metastases should be deemed amenable by the international multidisciplinary expert team for radical local treatment
* WHO performance status 0-2
* Indication for checkpoint inhibition and/or targeted therapy
* PD-L1 with a CPS of 1 or higher as per local clinical practice for immunotherapy use
* HER2 overexpression as per local clinical practice for trastuzumab use
* Claudin 18.2 overexpression as per local clinical practice for zolbetuximab use.
* Any other biomarker that allows targeted therapy in first line approved by EMA
* No prior systemic therapy for metastatic disease
* CT-scan ≤8 weeks prior to inclusion
* Ability to undergo local treatment and start systemic treatment beyond 18 weeks of total systemic treatment.
Exclusion Criteria
* Brain metastases
* Peritoneal or pleural carcinomatosis
* Patients with MSI dMMR
* Uncontrolled immunodeficiency (e.g. AIDS)
* Peripheral neuropathy \>CTCAE grade 1, precluding start of full dose oxaliplatin treatment
* Both organ metastasis and extra-regional lymph node metastasis
* Conditions precluding local treatment or systemic therapy for oligometastatic disease:
* Serious medical comorbidities precluding local treatment (e.g., interstitial lung disease in patients with pulmonary metastasis)
* Clinical or radiological evidence of spinal cord compression or epidural tumor within 2 mm of the spinal cord
* Simultaneous other malignancy or previous other malignancy with a disease-free period of \<5 years, except adequately treated non-melanoma skin cancer or in-situ cancers
* Uncontrolled (bacterial) infections
* Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments
* Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias
* Continuous use of immunosuppressive agents equivalent to \>10 mg daily prednisone
* Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine
* Pregnancy or breast feeding
* Patients (M/F) with reproductive potential not implementing adequate contraceptive measures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UMC Utrecht
OTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hanneke W. M. van Laarhoven
prof . dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter van Rossum, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Amsterdam UMC
Richard van Hillgersberg, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UMC Utrecht
Hanneke van Laarhoven, MD, PhD, PhD
Role: PRINCIPAL_INVESTIGATOR
Amsterdam UMC
Tiuri Kroese, MD, PhD
Role: STUDY_DIRECTOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amsterdam Univeristy Medical Center
Amsterdam, , Netherlands
UMC Utrecht
Utrecht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Description of the complete OMEC protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OMEC-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.